Literature DB >> 28980483

Clinical outcomes following primary percutaneous coronary intervention for ST-elevation myocardial infarction according to sex and race.

Arvindra Krishnamurthy1,2, Claire Keeble1, Natalie Burton-Wood2, Kathryn Somers2, Michelle Anderson2, Charlotte Harland2, Paul D Baxter1, James M McLenachan2, Jonathan M Blaxill2, Daniel J Blackman2, Christopher J Malkin2, Stephen B Wheatcroft1,2, John P Greenwood1,2.   

Abstract

BACKGROUND: Female sex and South Asian race have been associated with poor clinical outcomes following primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) but remain understudied in large real-world series. We therefore investigated the association of sex and race with clinical outcomes following PPCI.
METHODS: We conducted a prospective study of all patients undergoing PPCI for STEMI between January 2009 and December 2011 at a large UK cardiac centre. Clinical characteristics and outcomes were compared according to sex and race using Chi-square test, independent samples Student's t-test and Mann-Whitney U-test. Primary and secondary outcomes were 12-month major adverse cardiovascular events (MACEs) - defined as all-cause mortality, myocardial infarction and unplanned revascularization, analysed using Cox proportional hazard models adjusting for cardiovascular risk factors.
RESULTS: Three thousand and forty-nine patients were included. Women ( n=826) were older than men ( n=2223) (median age 69 vs. 60 years, p <0.01). Mortality (hazard ratio 1.48 (1.15-1.90)) and MACE (hazard ratio 1.40 (1.14-1.72)) were higher in women in univariable analysis. However, there were no significant sex-differences in mortality or MACE after age-stratification alone. Multivariable analysis also showed no significant differences in outcomes between sexes. South Asians ( n=297) were younger but had a higher prevalence of most risk factors than White patients ( n=2570). Mortality and MACE did not differ significantly between South Asian and White patients in univariable or multivariable analysis.
CONCLUSION: MACE and mortality was not greater in women, or in South Asian patients following PPCI after adjustment for cardiovascular risk factors including age, which was most strongly associated with both outcomes.

Entities:  

Keywords:  Female; ethnic groups; myocardial infarction; percutaneous coronary intervention

Mesh:

Year:  2017        PMID: 28980483     DOI: 10.1177/2048872617735803

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  4 in total

Review 1.  Interaction Between Race, Ethnicity, Severe Mental Illness, and Cardiovascular Disease.

Authors:  Kevin O'Gallagher; James Th Teo; Ajay M Shah; Fiona Gaughran
Journal:  J Am Heart Assoc       Date:  2022-06-14       Impact factor: 6.106

2.  Gender differences in clinical outcomes of acute myocardial infarction undergoing percutaneous coronary intervention: insights from the KAMIR-NIH Registry.

Authors:  Myunhee Lee; Dae-Won Kim; Mahn-Won Park; Kyusup Lee; Kiyuk Chang; Wook Sung Chung; Tae Hoon Ahn; Myung Ho Jeong; Seung-Woon Rha; Hyo-Soo Kim; Hyeon Cheol Gwon; In Whan Seong; Kyung Kuk Hwang; Shung Chull Chae; Kwon-Bae Kim; Young Jo Kim; Kwang Soo Cha; Seok Kyu Oh; Jei Keon Chae; Ji-Hoon Jung
Journal:  J Geriatr Cardiol       Date:  2020-11-28       Impact factor: 3.327

3.  Ethnic differences between South Asians and White Caucasians in cardiovascular disease-related mortality in developed countries: a systematic literature review.

Authors:  Mubarak Patel; Salim Abatcha; Olalekan Uthman
Journal:  Syst Rev       Date:  2022-09-29

4.  Association between operator volume and mortality in primary percutaneous coronary intervention.

Authors:  Arvindra Krishnamurthy; Claire M Keeble; Michelle Anderson; Natalie Burton-Wood; Kathryn Somers; Charlotte Harland; Paul D Baxter; Jim M McLenachan; Jonathan M Blaxill; Daniel J Blackman; Christopher J Malkin; Stephen B Wheatcroft; John P Greenwood
Journal:  Open Heart       Date:  2022-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.